Pharmaceutical Solutions: CRO of Choice in Australia and New Zealand

Pharmaceutical Solutions is a New Zealand and Australian based independent CRO, offering personalised clinical research management and regulatory services to the biotechnology and pharmaceutical industry. 

We are proud to promote quality clinical research in our region and proud of our contribution to improving people’s health and wellbeing.

We work closely with you to deliver your project expectations from study design, speed of approval, patient recruitment numbers and quality, to completing the study. We can then work with you to provide Regulatory support to commercialise your product.





Christmas greetings and best wishes from the team at PSL.

Like most of you, our "inboxes" reflect a busy time of the year. In general, we think the growing enquiries to conduct clinical studies in New Zealand and Australia reflect buoyancy and positivity as we focus on 2017. The region continues to offer politically stable environments with sound regulatory authorities. We see continued population growth reflecting a "World need" to address health issues like diabetes, and age related diseases. We are aware of fresh funding available to research institutions through partnerships. New Zealand's profile rates high with Biotech companies. At Pharmaceutical Solutions we are upbeat about the new year and wish you all a heartfelt Christmas hopefully distanced from that inbox.

Fast Approval

This week we celebrated with a client the success of a clinical trial approval through New Zealand Medsafe and Ethics in super quick time

Document Review: 5 days
Medsafe Approval: 22 days
Ethics Approval: 18 days 

Proficient review of documents and efficient processes to address any queries, as well as a good understanding of Medsafe and Ethics timelines are good reasons to work with Pharmaceutical Solutions to conduct clinical research in Australia and New Zealand.

Pharmaceutical Solutions works with New Zealand local authorities and sites to achieve first patient recruitment for global study.

Client Announces First Patient Dosed in Phase 2 Study of Pegylated Interferon Lambda in Hepatitis D Virus (HDV) Infection

LIMT HDV: Lambda Interferon MonoTherapy in HDV Study

Focused on the development and commercialization of targeted therapies for rare diseases, the client announced today that the first patient was dosed in the Phase 2 LIMT HDV (Lambda Interferon MonoTherapy in HDV) study, a monotherapy trial of pegylated interferon lambda 1a ("Lambda") as a potential treatment for chronic hepatitis D virus (HDV) infection.  LIMT HDV is a 30-patient study designed to evaluate the safety, tolerability and efficacy of two dose levels of Lambda after 48 weeks of treatment.  LIMT HDV is an international study currently enrolling at University of Auckland in New Zealand.